Literature DB >> 31622195

The predictive role for ST2 in patients with acute coronary syndromes and heart failure.

Vasiliki Tsigkou1, Gerasimos Siasos1, Evanthia Bletsa1, Maria- Evi Panoilia1, Angeliki Papastavrou1, Georgios Kokosias1, Evangelos Oikonomou1, Nikolaos Papageorgiou1, Marina Zaromitidou1, Georgios Marinos1, Manolis Vavuranakis1, Christodoulos Stefanadis2, Athanasios G Papavassiliou3, Dimitris Tousoulis1.   

Abstract

Intensive research has shed light to the utilization of novel biomarkers which facilitate the diagnosis and prognosis of patients with different medical problems. One of the most important biomarkers especially in the spectrum of heart failure is soluble ST2 (sST2, soluble suppression of tumorigenicity 2), which is involved in inflammation, fibrosis and cardiac stress. In the revised 2017 ACC/AHA/HFSA "Focused Update Guidelines for the Management of Heart Failure" ST2 was given a class-IIa recommendation for the optimal risk assessment in patients with heart failure. Many studies indicate that not only baseline but also serial measurements of ST2 can accurately predict future cardiovascular events in patients with acute coronary syndromes and heart failure. Therefore, in this review we are going to discuss the studies about the prognostic significance of ST2 in patients with acute coronary syndromes, acute and chronic heart failure. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  acute coronary syndromes; biomarkers; coronary artery disease; heart failure; prognosis

Year:  2019        PMID: 31622195     DOI: 10.2174/0929867326666191016121630

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

1.  Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention.

Authors:  Shu-Min Chang; Yan-Tan Yu; Bo Luan; Ai-Jie Hou; Yong Wang
Journal:  J Interv Cardiol       Date:  2022-04-15       Impact factor: 1.776

2.  MicroRNA-338-3p as a therapeutic target in cardiac fibrosis through FGFR2 suppression.

Authors:  Cheng Huang; Rui Wang; Jianjun Lu; Yongli He; Yueheng Wu; Wuxia Ma; Jindong Xu; Zejia Wu; Zhe Feng; Min Wu
Journal:  J Clin Lab Anal       Date:  2022-07-06       Impact factor: 3.124

3.  Predictive values of sST2 and IL-33 for heart failure in patients with acute myocardial infarction.

Authors:  Jingxian Xing; Junyan Liu; Tao Geng
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.